Press Releases

MGEN $0.97 $ + 0.29 (42.67%)

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
1/23/2020
8:00 AM ET
Press Release

miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma at Two Upcoming Conferences

1/23/2020

BOULDER, Colo., Jan. 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...

 Continue Reading
12/11/2019
4:05 PM ET
Press Release

miRagen Announces Major Changes to Company’s Strategy

12/11/2019

Expecting topline data in Q3 2020 from truncated Phase 2 SOLAR clinical trial of cobomarsen in CTCL Pursuing guidance from FDA on a clinical development plan for cobomarsen in ATLL; anticipate meeting...

 Continue Reading
11/26/2019
8:00 AM ET
Press Release

miRagen to Present at the Evercore ISI HealthCONx Conference 2019

11/26/2019

BOULDER, Colo., Nov. 26, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...

 Continue Reading
11/7/2019
4:01 PM ET
Earnings Release

miRagen Reports Third Quarter 2019 Results and Provides Corporate Update

11/7/2019

Announced positive data from two Phase 1 clinical trials of MRG-110Remain on track to announce interim top-line data from its Phase 2 clinical trial of remlarsen in keloids by year endImplemented rest...

 Continue Reading
10/28/2019
9:00 AM ET
Press Release

miRagen to Present at the DIA/FDA Oligonucleotide-Based Therapeutics Conference Today

10/28/2019

An overview of its second-generation miR-29 mimicsClinical development of its microRNA inhibitors BOULDER, Colo., Oct. 28, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clini...

 Continue Reading
Displaying 1 to 5 (of 89 releases)